ticagrelor and Diarrhea

ticagrelor has been researched along with Diarrhea* in 1 studies

Other Studies

1 other study(ies) available for ticagrelor and Diarrhea

Article	Year
Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event. BMJ case reports, 2021, Jul-07, Volume: 14, Issue:7 Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms. Topics: Acute Coronary Syndrome; Aged; Diarrhea; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor	2021

Article

Year

Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event.

BMJ case reports, 2021, Jul-07, Volume: 14, Issue:7

Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.

Topics: Acute Coronary Syndrome; Aged; Diarrhea; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor

2021